SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Robohogs who wrote (10107)6/14/2007 12:22:00 PM
From: Iamarangerboy   of 10280
 
reuters.com

Sepracor hikes price of Lunesta sleep drug-analyst

BOSTON, June 14 (Reuters) - Sepracor Inc. (SEPR.O: Quote, Profile, Research) has raised the price of its insomnia drug Lunesta by 9 percent as the company moves to shore up the drug amid tepid prescription growth, according to an analyst at American Technology Research.

The price increase comes on the heels of a 9 percent increase last November, said analyst Manoj Garg in a research note.

Despite the introduction in April of a generic version of the rival sleep drug Ambien, Lunesta is maintaining a steady market share of about 13.5 percent, Garg said.

"The most recent price increase could offset prescription weakness seen for the franchise, and likely assist in stabilizing second-half Lunesta revenue," according to the research note.

A report earlier this week from John LeCroy, an analyst at Natexis Bleichroeder, noted that weekly trends showed Lunesta running below his sales estimates for the quarter.

While the drug picked up 1.8 percent in total prescription market share since the entry of generic Ambien, he said the gains are due to a recent drop in generic Ambien prescriptions and not due to a pick-up in Lunesta prescriptions.

Officials at Sepracor were not immediately available for comment.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext